ELLIS MARTIN REPORT: CARDIOL THERAPEUTICS CEO DAVID ELSLEY:PHASE III MAVERIC - WHAT COMES NEXT $CRDL - CARDIOL THERAPEUTICS INC

Explicit Guidance:

• No financial guidance provided regarding revenue, earnings, margins, capex, cash flow, or capital structure; company is pre-revenue and focused on clinical development.
• Top-line readout timeline: Expected in 2027 for the Phase 3 Maverick trial.
• Regulatory timeline: Plan to submit New Drug Application (NDA) immediately following the 2027 readout, with no specific submission date given other than "as fast as possible."

Business-Segment Outlook:

• Core Therapy (CardioRx): Pivotal Phase 3 Maverick trial for recurrent pericarditis is active; trial size increased from 110 to 150 patients to ensure statistical power given lower-than-anticipated recurrence rates in the treatment arm.
• Trial Extension: Additional 3 months added to the originally planned 2-year study duration to finalize the dataset.
• Pipeline (Archer Program): Program targeting myocarditis (inflammation of heart muscle) has shown potential structural improvement in patients; distinct from the pericarditis program but related in mechanism and patient demographic.
• Target Demographic: Patients aged 35–55 (pre-morbid, generally healthy) suffering from recurrent pericarditis, and younger athletes at risk for lethal myocarditis.
• Addressable Market: Targeting "tens of thousands" of patients currently lacking effective treatment options for recurrent pericarditis; pericarditis described as a "rare disease" with high unmet need.

Market and Competitive Outlook:

• Competitive Landscape: Current standard of care includes steroids (poorly tolerated, significant toxicity) and biologics (injectable, immune-suppressing, prohibitively expensive at $300,000/patient/year).
• Differentiation: CardioRx is positioned as an oral, non-immune-suppressing therapy that is potentially disease-modifying (allowing patients to discontinue treatment and live normally), contrasting with current therapies that require lifelong use or defer disease.
• Distribution Advantage: Oral formulation enables dispensing through standard pharmacy channels, removing the need for specialized clinics and injection training required by biologics, potentially improving pricing accessibility for reimbursers.
• Market Awareness: Pandemic era increased awareness of inflammatory heart diseases, potentially improving clinical trial execution efficiency and patient recruitment.

Macro / Industry Outlook:

• Regulatory Pathway: Company aims to secure regulatory approval via the expanded Phase 3 data to support an NDA; trial design was conservative to ensure detection of a 40% reduction in risk (targeting 70% reduction observed in Phase 2).
• Industry Trend: Shift in focus toward "disease-modifying" capabilities rather than symptom management in inflammatory cardiac conditions.

Strategic Initiatives:

• Trial Expansion: Decided to expand Maverick trial enrollment to 150 subjects mid-study to maintain statistical power against lower-than-expected event rates.
• Academic Partnerships: Trials conducted at preeminent centers, specifically the Mayo Clinic and Cleveland Clinic, leveraging their status as having the two largest pericardial practices globally.
• Clinical Data Dissemination: Phase 2 data published in the Journal of the American Heart Association to educate the cardiology community and patient base.

Risks and Headwinds to Outlook:

• Trial Blinding: Current recurrence rate observations are not split by treatment vs. placebo (trial remains blinded); company estimates placebo group relapse at 75–80% based on historical data.
• Event Rate Variability: The observed reduction in patients getting sick may be lower than anticipated due to conservative powering; if the drug effect is stronger than the 40% threshold used for powering, the original sample size might have been insufficient without expansion.
• Regulatory Uncertainty: Final product availability is contingent on outcomes meeting regulatory standards; no guarantee of approval is stated.
• Disease Complexity: Distinguishing between pericarditis (non-lethal, quality-of-life destroying) and myocarditis (potentially lethal) remains a clinical consideration for the broader program.

Management Tone on the Future:

• Confidence Level: High confidence in the drug's potential; describes current progress as "extremely exciting" and the trial design as "conservative" to avoid missing a treatment effect.
• Strategic Certainty: Expressed strong belief in the "disease-modifying" potential, stating patients "won't require our drug for the rest of their life."
• Pacing: Emphasis on efficiency and speed ("as fast as possible") to reach the patient community, acknowledging the desperate need for alternatives.

Miscellaneous:

• Company: Cardio Therapeutics (NASDAQ/TSX: CRDL).
• Lead Candidate: CardioRx (investigational oral therapy).
• Current Trial Status: Phase 3 Maverick trial for recurrent pericarditis; Phase 2 data confirmed 70% risk reduction.
• Investor Communication: Company engaging with investors and physicians to highlight the "largest if not the largest" pivotal Phase 3 trial in this specific indication.